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Ketamine for Depression:
A Mixed-Methods Study 
Prior studies have reported variously on the presence or absence of dissociative effects at 
subanesthtetic doses of ketamine administered for treatment-resistant depression. This mixed-
methods study emulated the protocol used for the studies in question, with IV administration 
of 0.5mg/kg over 40 minutes with eight experienced ketamine users. Quantitative measures 
were generally insignificant since this was not a population reporting depression; blood 
pressure increased as expected by 20-30mm systolic and 6-20mm diastolic, falling rapidly 
by 20 minutes after completion of the infusion. Individual qualitative reports reports of 
relaxation, pleasant sensation, decreased cognitive function, and some disabling of ordinary 
capacities. As experienced users, subjects commented freely on what was characterized as 
the triviality of the experience, and typically expressed skepticism that ketamine could 
have antidepressant properties when administered at this dose or in this manner, as well as 
disbelief that it could be beneficial except perhaps as a period of relaxation, or as a partial 
break from ordinary states of mind in naïve subjects. Group discussion produced a consensus 
recommendation in favor of threshold- and higher-dosage transformative work beginning 
with a 40-50mg IM bolus, potentially in a series of sessions with higher dosages if indicated, 
with the number of sessions to be determined by clinical practice; such work should occur 
in a closely monitored psychotherapeutic setting.  
International Journal of Transpersonal Studies, 33(2), 2014, pp. 75-83 
Philip E. Wolfson 
Center for Transformational Psychotherapy 
San Francisco and San Anselmo, CA, USA  
Keywords:  Ketamine, dissociative anesthetic, intramuscular, psychedelic, antidepressant, 
treatment-resistant depression, antidepressant, phenomenology, qualitative, mixed methods
Ketamine is a dissociative anesthetic that has recently shown potential as a significant new antidepressant (Duman & Agajanian, 2012). 
Unlike existing antidepressants that target serotonin, 
norepinephrine, and dopamine systems--and that may 
take a number of weeks to achieve efficacy, ketamine is 
an NMDA receptor antagonist that affects the glutamate 
system and appears to provide significant relief to some 
individuals within only hours or days (Ryan, Marta, & 
Koek, 2014 [this issue]). These findings are of importance 
for two reasons: first, because the slow onset of relief from 
conventional medications leaves a window of vulnerability 
for individuals suffering from severe depression or 
suicidality; and second, because current antidepressant 
treatments fail in approximately 25-50% of individuals 
treated (Little, 2009; Nemeroff, 2007; Souery, Papakostas, 
& Trivedi, 2006), and in some cases may actually worsen 
outcomes (Gueorguieva, Mallinckrodt, & Krystal, 2011). 
Even when there is clinical response to current 
antidepressants, the results are only somewhat better than 
placebo (Kirsch & Sapirstein, 1998; Kirsch et al., 2008; 
Moncrieff & Kirsch, 2005), especially for individuals 
whose depressive symptoms are mild to moderate 
at baseline (Fournier et al., 2010). It even has been 
suggested that the benefits actually conferred may be due 
to the psychological impact of non-specific physiological 
effects (Kirsch & Sapirstein, 1998; Moncrieff, 2007), 
and in any case such benefits may decrease over time 
(Goldberg, Privett, Ustun, Simon, & Linden, 1998). 
While individuals with the most severe depression show 
greater benefits from medication relative to placebo 
(Fournier et al., 2010), possibly this is the result of a 
lower response rate to placebo in such cases rather than 
enhanced drug efficacy (Kirsch et al., 2008). With the 
limited success of current pharmacological antidepressant 
strategies and the paucity of progress in the development 
of new antidepressant drugs (Hendrie & Pickles, 2013), 
pharmacological treatment has stagnated. The poor long-
term outcomes for current depression treatment (Fekadu 
et al., 2009; Goldberg et al., 1998; Kiloh, Andrews, & 
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Nielson, 1988; Tuma, 2000), together with its relatively 
high incidence (Kessler et al., 2003) and great societal 
impact (McKenna, Michaud, Murray, & Marks, 2005; 
Murray & Lopez, 1997), suggest that new antidepressant 
strategies could be of considerable value. 
While there has been growing public interest 
in the potential of ketamine, the robust nature of 
ketamine as a stand-alone treatment for depression and 
other psychiatric diagnoses has yet to be convincingly 
demonstrated. Short-term relief lasting from minutes 
to a few days has been the rule, particularly with single 
ketamine sessions (Katalinic et al., 2013), and this may be 
extremely important in crisis situations where immediate, 
even if not sustained, relief can be lifesaving. When 
administration is repeated and provided in concert with a 
variety of psychotherapies supporting the sustained and/or 
intermittent use of the drug, there has also been reported 
success (e.g., Khorramzadeh & Lofty, 1973; Kolp et al., 
2014 [this issue]; Krupitsky & Grinenko, 1997). The jury 
is still out, however, on long-term maintenance dosages 
of of ketamine for treating depressions but, despite this 
lack of clarity, ketamine as a Schedule III drug with 
a long history of safe use has become a growing part of 
the psychiatric arsenal with individuals and clinics—
including anesthesiologists—administering the substance 
in varying ways (Ryan et al., 2014 [this issue]).
Characteristic of the increased popularity of 
ketamine treatment has been a specific methodology 
designed to minimize ketamine’s potentially powerful 
psychedelic effects, which are nevertheless difficult 
to eliminate entirely. The psychedelic properties of 
ketamine may remain present to some degree, even 
when administered in the small dosages typically used in 
studies that attempt to establish its efficacy for depression. 
Seeing these as undesirable appears to be based on the 
assumption that such “side-effects” are both negative and 
separable from its antidepressant properties.
Ketamine has been recognized for its psychedelic 
properties since 1965, through underground use and a 
few publications (cf. Jansen, 2004; Kolp et al., 2014 [this 
issue]). The first study to intentionally examine ketamine’s 
psychedelic effect at subanesthetic doses was published in 
1985 by Golechha, Rao, and Ruggu, reporting on the 
use of 1mg/kg administered intramuscularly (IM) in two 
males, 51kg and 61kg respectively, with the stated purpose 
of narcoanalysis. Early reports suggested an emotionally 
beneficial effect from such doses, which are large enough 
to produce psychedelic experiences that could be 
considered transformational. These often resulted in what 
was sometimes called a psychedelic afterglow, tending 
to last for significant periods of time after the ketamine 
sessions, and suggesting an antidepressant effect. It 
seems possible that such experiences may have led to the 
subsequent exploration of ketamine as an antidepressant. 
Later research has de-emphasized ketamine’s 
psychedelic properties—perhaps considering these to be 
a stigma that might impede its psychotherapeutic use. 
Krystal, along with Charney and other colleagues (1994) 
at the National Institute of Mental Health, deserve credit 
for the development of what might be referred to as the 
“NIMH protocol,” with publication of a paper examining 
its sub-anesthetic effects. In this first paper from a group 
with Charney as its principal investigator, psychedelic 
effects were still recognized, even though considered as 
undesirable. Krystal et al. (1994) reported that:
Ketamine (1) produced behaviors similar to the 
positive and negative symptoms of schizophrenia; 
(2) elicited alterations in perception; (3) impaired 
performance on tests of vigilance, verbal fluency, 
and the Wisconsin Card Sorting Test; (4) evoked 
symptoms similar to dissociative states; and (5) 
preferentially disrupted delayed word recall, sparing 
immediate recall and post-distraction recall. (p. 199)
Research teams including Charney—illustrating 
continuity in the development of this research—published 
results from randomized, placebo-controlled, double-
blind studies of ketamine’s impact on major depression in 
2000 (Berman et al.) and 2006 (Zarate et al.). These two 
studies demonstrated rapid and robust antidepressant 
response to a single dose of ketamine using the NIMH 
protocol, with effect lasting 72 hours or more in 12 of 
25 total patients; relapse occurred in all but two patients 
in less than two weeks post ketamine infusion. By 2010 
aan het Rot and colleagues, again including Charney, 
had moved from a single dose of ketamine to a series of 
six infusions administered over 12 days, each infusion at 
the same dosage that had previously proven efficacious 
in single-dose treatment. Response criterion was met by 
nine of ten patients after the first infusion as well as after 
the sixth. Patients who responded to the initial infusion 
maintained their response for as long as they received 
additional doses and for at least six days after that. Four 
of nine patients relapsed less than 2 weeks post-ketamine 
treatment.  Eight of nine patients relapsed between 6 and 
45 days, the average being 19 days, with one patient’s 
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antidepressant effect lasting for more than three months. 
Interestingly, aan het Rot et al (2010) designed this 
study to be comparable with electroconvulsive therapy 
(ECT)—which they noted also showed high relapse rates 
in the month after discontinuation of shock therapy.
Krystal et al.’s (1994) initial report of the effects of 
the NIMH protocol is markedly different from that offered 
by aan het Rot et al. when the latter team replicated the 
NIMH protocol in 2010. They commented, “Ketamine 
elicited minimal positive psychotic symptoms. Three 
patients experienced significant but transient dissociative 
symptoms. Side effects during and after each ketamine 
infusion were generally mild” (p. 139). Note that Krystal 
et al.’s (1994) report of “positive and negative symptoms 
of schizophrenia” (p. 199) changes to “positive psychotic 
symptoms” in aan het Rot et al. (2010, p. 139); these were 
now “minimal,” dissociative symptoms, were “transient” 
and limited to a small subset of participants, and side 
effects were “generally mild” (p. 139). This significant 
shift in emphasis—little short of a reversal of findings—
occurred with the same drug, administered at the same 
dose, with at least one principal investigator common to 
both teams; apparently something else had changed.  
As a further complication, in 2014 a team led 
by Zarate (Luckenbaugh et al.)—first author on one of 
the studies that included Charney—reported that in an 
analysis of their data from 108 patients who received single 
subanesthetic infusions of ketamine, the only variable in 
their data predictive of a sustained antidepressant response 
was the presence of dissociative side effects. Other 
agents that, like ketamine, act as NMDA antagonists 
but lack ketamine’s dissociative effects have thus far 
been ineffective in producing antidepressant effects 
(Zarate et al., 2013). Conversely, a study of the impact 
of the dissociative anesthetic nitrous oxide on 20 subjects 
diagnosed with treatment resistant depression yielded 
outcomes similar to ketamine (Nagele et al., 2014). Such 
findings raise the question of whether the antidepressant 
effect comes from a specific chemical interaction in 
the brain, whether a particular state of mind may have 
some beneficial effect irrespective of the chemical used 
to induce that state (cf. Moncrieff & Cohen, 2006), or 
whether similar dissociative states may yield comparable 
benefits through different in brain effects.
The lack of consistency in reporting sensory 
effects of ketamine during IV administration of the 
NIMH protocol provided incentive to undertake this 
study analyzing participants’ phenomenal experiences of 
the dissociative effects of ketamine using the same dosage 
rate and method of administration as the NIMH protocol. 
This represented an effort to gather specific data on the 
presence or absence, and the nature, of any psychedelic 
symptoms as reported by Krystal et al. (1994), aan het 
Rot et al. (2010), and others.
The Study
This study was designed to gather evidence regarding the presence or absence of dissociative effects from 
ketamine, as well as on the qualities of any such effects 
and how they might compare with qualities at higher 
doses, working with experienced ketamine users who 
volunteered to receive doses consistent with the NIMH 
intravenous (IV) ketamine protocol followed by the 
Charney teams (Krystal et al., 1994; Collins et al., 2010). 
Selected vital signs were measured at intervals, and 
qualitative reports were collected after the experience. The 
latter are situated in the tradition of qualitative research on 
psychedelics, such as DMT, ayahuasca (Bouso, Fábregas, 
Antonijoan, Rodriguez-Fornells, & Riba, 2013), and 
marijuana (Lile et al., 2013); it is also resonant with the 
new Johns Hopkins experienced users study currently 
enrolling subjects by Griffiths (2015) and his group, 
which randomizes 20 subjects to five experiences each of 
18 different possible psychoactive substances and placebo.
Participants
Eight subjects with at least five prior ketamine 
experiences at boluses of 50mg or higher, and with no 
ketamine dependency or negative health effects from 
ketamine use, were recruited by word of mouth for the 
study. All but one of these had had more than 20 previous 
ketamine experiences, with dosage ranging from boluses 
of 50mg to 130mg; all reported a history of positive 
and transformative experiences at the higher IM doses. 
All participants shared a longitudinal awareness of their 
own and others’ ketamine experiences over time—a 
process years to decades in duration. In pre-intervention 
interviews, participants expressed a sense of their lives 
changing over time—with some depressive episodes, 
relationship upheavals, and emotional difficulties—yet 
each expressed a sense of gratitude and appreciation 
for the transformative experience that had occurred 
with ketamine use, affecting their lives and minds 
predominantly in a positive manner. None reported 
depression at the time of the study.
Measures
Blood pressure, pulse rate, oxygen saturation, 
and respiratory rates were collected, and the Beck 
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Depression Inventory (BDI; Beck, Steer, & Carbin, 1988) 
was administered pre- and post-intervention. Qualitative 
reports were gathered during and after the intervention, 
and subjects discussed the experience in context of their 
own previous ketamine use at higher dosages.
Procedure
As a first step, medical personnel took baseline 
measures of blood pressure, pulse rate, and oxygen 
saturation for each subject, and the BDI was administered. 
Subsequently, but prior to ketamine administration, 
subjects spent 15 minutes relaxing in silence. Ketamine 
was then administered to subjects, who were lying 
down, through IV saline drip at a dosage of 0.5 mg/kg 
over 40 minutes. The intervention took place in a quiet 
atmosphere, with gentle music deemed to have a “spiritual” 
quality played throughout the process; the same music 
was used for all subjects. Blood pressure, pulse rates, 
oxygen saturation and respiration rates were assessed 20 
minutes into the study and 20 minutes after completion 
of the infusion. Subjective data were accumulated by non-
participant administrators who charted, for each subject, 
observations, periodic inquiries, assessment of mental state, 
and degree of psychedelic effect observed and reported, 
if any. Following completion of the IV infusion, subjects 
spent an additional hour in quiet with communication 
only as necessary. The BDI was completed again at the 
end of this reflective period, and a copy was taken home 
for completion on the following day. After the reflective 
period, participants engaged in a group discussion.
Results
All eight subjects completed the experience 
without complications. Return to baseline was reached 
within 30 minutes to one hour following completion of the 
infusion.  All subjects were fully ambulatory at completion 
of the infusion with some residual psychomotor slowing. 
Two subjects reported mild nausea during the infusion. 
Several subjects ate vigorously after completion of the one-
hour post infusion rest phase. One subject complained of 
an unusual and moderately severe headache for her, which 
began 3 hours after completion and lasted two hours. 
Another subject reported mild headache of brief duration.
Pulse rate, oxygen saturation, and observed 
respiratory rate. These measures did not change from 
baseline during the course of ketamine administration.
Blood pressure. Blood pressure measurements 
increased above baseline for all subjects: 20-30mm 
systolic, and 6-20mm diastolic, falling rapidly by 20 
minutes after completion of the infusion. 
BDI. There were no significant changes in BDI 
score, but subjects were not depressed at the onset of the study. 
Observations. Reported visual effects and 
withdrawal from usual visual sensations were the primary 
sensory effects. Auditory experience was mildly affected 
if at all, and the tactile sense was not noticeably impacted. 
Subjects remained responsive to auditory exchanges 
and responded appropriately to promptings, though 
at times more slowly and with reduced commentary. 
Environmental awareness was clearly diminished. 
Subjects who received higher doses of ketamine tended 
to report deeper experiences, regardless of their weight.
Qualitative reports. Descriptive comments 
during the experience included reports of relaxation, 
pleasant sensation, decreased cognitive function, and 
some disabling of ordinary capacities (Table 1). As 
experienced users, subjects commented freely on what was 
characterized as the triviality of the experience—a period 
of “OK” relaxation and mildly increased inner awareness, 
with little if any affective modulation. Subjects typically 
expressed skepticism that ketamine could have sustained 
antidepressant properties when administered at this dose 
or in this manner, and consensus that the experience was 
best described as a very partial break from ordinary states 
of mind. Seven subjects indicated no desire to repeat 
the experience. One female subject felt changed by the 
experience, later reporting that she felt “emotionally very 
well” for several weeks, with increased motivation; she 
said she “would do it again.” 
Participant discussion and evaluation. In 
discussion, a consensus recommendation emerged 
from the group: for threshold- and higher-dosage 
transformative work, beginning with a 40-50mg IM 
bolus, potentially in a series of sessions with higher 
dosages if indicated with the number of sessions to be 
determined by clinical practice; should occur in a closely 
monitored psychotherapeutic setting.  
Also informed by the group discussion, it was 
suggested that goals of ketamine assisted psychotherapy 
should include facilitating a transformative experience in 
relationship to one’s own ego that would potentially have 
as its effect the reduction of obsessions through some 
breakage of continuity of afflictive mind, reformation 
of consciousness, reevaluation of the past and, hence, 
future prospects. In addition, there is the novelty and 
uniqueness of an experiential state, one that, to paraphrase 
participants, tends to produce a relaxation of that sense 
of control that attempts to keep the mind from deviating 
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 Table 1. Notes on Participant Responses and Reports
Subject 1    At 5 minutes—“usual sensations” of beginning of a K experience; “warm and floating”; mild
       At 20 minutes—“didn’t seem like 15 minutes have gone by”; building—“higher than 10 minutes ago”
       not particularly psychological
       At 35 minutes—not shamanic, not empathogenic, no disinhibition, no loss of intellectual function; 
       floaty, soft, diffuse sensations in body
       10 minutes post-infusion—shouldn’t drive, but could; stayed pretty much in contact
Subject 2     At 15 minutes— “something happening,” metallic taste
        At 35 minutes—very pleasant, “definitely K,” warm, no hallucinations, mindful, “paper baggy,” “crinkly,”
        could read or make phone calls
Subject 3     No report during administration (highest dose, 50 mg). While not clinically depressed prior to trial,
        had flat-ish affect 
        2 weeks afterwards—has felt emotionally very well. Baseline reclusiveness seems comfortable and
        basic inertia is less compelling—a little more willing to get out of her chair
        “Dose was pretty much perfect”—both out and in, aware and able to talk—and remember most of it;
        reported that session seemed to go by faster than an hour; “I would do it again”
Subject 4     At 5 minutes—a little relaxation; cold hands
        At 20 minutes—mildly relaxed, “krinkly paper bag feeling,” +2 of 4 (Shulgin scale); would not make 
        phone calls; “now I want to close my eyes”; slightly disabling—feel cognitively sloppy, a little drunk;  
        past experience with 50mg. ketamine lozenge was “stronger than this”
        At 40 minutes—“paper bag tongue,” tinnitus. “I do not think this [treatment protocol] is advantageous 
        or preferred”
Subject 5     At 10 minutes—+2 of 4 (Shulgin scale); would rather keep eyes closed
        At 20 minutes—“door almost open,” +2 (Shulgin scale)
        At 25 minutes—“I definitely don’t want to open my eyes,” +2½ (Shulgin scale)
        At 30 minutes—some nausea, “an ugly 2½” (Shulgin scale)
        5 minutes post—“Whew!”; quite “stoned” and nauseated; “I’d never do this again. This is not an 
        anti-depressant!”
Subject 6     At 7 minutes—“something happening,” mild, metallic taste, +/- (Shulgin scale)
        At 20 minutes—high, “loopy,” no hallucinations, “can’t let go of obsession”
        At conclusion—”I’d not spend money for this”
Subject 7     At 5 minutes—comfortable, peaceful, “going flowey”
        At 11 minutes—“very high,” smiley, numb hands
        At 20 minutes—floating, eyes closed, “I don’t want to talk”
        At finish—“laughy, bound in my chest,” with open eyes—fuzzy vision, peaceful, puffy eyelids, 
        can’t breathe deeply
Subject 8:    At 3 minutes—heaviness in head
        At 5 minutes—floaty, relaxed, “a familiar falling feeling but very gentle”
        At 20 minutes—“very, very relaxed,” “not particularly insightful, in my opinion—not conducive to
        therapeutic insight”
        At 35 minutes—very relaxed, less intense, “very dissolving,” could walk with support, 
        “couldn’t drive,” peaceful, very tuned into all sounds
from what one might believe to be conventional sanity. It 
is possible that this relaxing effect might lead to a more 
robust and enduring antidepressant response.
Discussion
Based on participant reports in this small group, 
the intramuscular (IM) route of administration initially 
appears to be safe, effective, and less burdened with a 
medical context that includes additional and costly 
technological infrastructure that is necessary when 
administering ketamine intravenously. It is well known 
from psychoactive research that a patient’s mood and 
the setting in which that research is conducted may 
have significant impact on the quality of the resultant 
experience. In such treatments a medicalized context 
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has the potential to create an alienating atmosphere that 
may diminish beneficial effect (e.g., Fadiman & Kornfeld, 
2013). Provision of IM ketamine offers the advantage 
of administration in a comfortable office setting, with 
appropriate safety measures available.  
The effects of ketamine appear to be related both 
to dose and to subject sensitivity, and only partially to body 
weight. In this study dosage was based on body weight at 
a rate of 0.5mg/kg. Subjects with greater body weight who 
received higher dosages had more of an anesthetic/sensory 
effect and reported deeper experiences. For example, a 
female subject who reported significant positive effects 
had the highest body weight, and received the highest 
dose (50mg). This outcome is consistent with the 
researcher’s experience that drug effect and body weight 
are related but not linearly correlated. It is generally the 
case with psychedelic and other psychoactive substances 
that individuals have a range of sensitivities irrespective 
of their actual weight, and that effects are the result of 
multiple factors, so that a dose that produces intoxication 
or profound experience in one individual may produce 
little or no response in another. 
Based on extensive experience with ketamine, 
it is possible to suggest that the sensory effects obtained 
with dosages used in the NIMH protocol are quite low 
within the range of effects produced by sub-anesthetic 
doses of ketamine. As ketamine dosage increases (as to a 
lesser extent with nitrous oxide) the sensory inputs and 
perceptual integrations of the senses are progressively 
turned off at the cortical level, leaving consciousness more 
and more subject to its own view, experience, and creativity. 
This state of mind, increasingly separated from external 
input, bears some similarity to a dream state or a near 
death experience—a heightened experience of internal 
consciousness with its own particular linkages fostered 
by ketamine. Tactile and visual perception are affected at 
doses of 30-40mg, and olfactory, gustatory, and auditory 
senses typically shift beginning at around 50mg. As 
dosage increases, penultimately, this unique consciousness 
itself diminishes and there is increasing memory loss of the 
experience—hence the limits on the amount of ketamine 
that is evocative of the state. Conscious awareness is 
significantly impacted at 150mg or higher, tending 
toward anesthesia as dosage increases. Beyond a certain 
dosage range this impact on consciousness is a self-evident 
drawback for an assisted psychotherapy experience. 
 Antidepressant substance treatments can be 
thought of in categories relating to effects on consciousness 
according to the schema I am elucidating below, each 
illustrated by typical examples, based on my experience as 
a psychiatrist: 
• Interruption of consciousness and breakage of 
the stream—ECT, narcoanalysis and induced 
sleep in a continuum to coma
• Disruption of consciousness, mild—NIMH IV 
protocol of ketamine
• Disruption, ego dissolution, and transfor-
mation—higher dose subanesthetic ketamine 
and other psychedelics
• Direct shifting of mood and new experiences of 
affect—MDMA and other empathogens
• Slow shifting of affective and anxious/obsessional 
states—conventional antidepressants such as 
SSRIs
• Potential affective smoothing, re-focus and 
obsession release—marijuana
In this context, IV ketamine administration at 
0.5mg/kg results in a mild disruption of consciousness, 
with a temporary release from a depressed affective and 
obsessional state; state shift usually does not persist 
much beyond the immediate effect of the experience, 
and ordinary mental states along with the habitual state 
of depression tend to resume quickly. Small disruptions 
in consciousness produce minor changes in the course of 
depression, in part because humans tend to ruminate and 
obsess, because character is hard to shift, because humans 
have an ongoing but changing experience of external 
conditions, because external conditions do not change 
due to having a ketamine session, and because individuals 
live in their own history and the history and culture of the 
external environment.
As noted, Luckenbaugh et al. (2014) indic-
ated that dissociative effects predicted a sustained 
antidepressant response. Subjects in this study who were 
experienced ketamine users received doses in accordance 
with the NIMH protocol that produced relatively mild 
dissociative symptoms, and most of these reported only 
minimal beneficial impact. This is consistent with studies 
that show the antidepressant effect at these low dose levels 
to be short-lived.
Summary and Conclusion
The effects of ketamine are related to dose and 
subject sensitivity. For the most part, the higher the dose, 
no matter what the route of administration, the greater 
the anesthesia and interference with sensory modes, the 
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greater the perceived internal stimulation and isolation of 
consciousness to mind-only phenomena. 
The antidepressant effect of the NIMH IV 
protocol tends to be short-lived and has only been extended 
by repeated administration of IV infusions and by being 
a component part of an extended psychotherapeutic 
modality.  
The rapid onset of action of ketamine as an 
antidepressant appears to be due to its disruption of 
ordinary consciousness and its anesthetic properties. 
There is much more work to be done to elucidate a specific 
antidepressant property of ketamine, separate from or 
attached to its dissociative effects.
With the possibility that higher doses may 
produce antidepressant and other positive effects that 
are more robust and sustained than with the NIMH IV 
protocol, further explorations of ketamine’s effectiveness 
are highly desirable, given the potential benefits of 
ketamine assisted psychotherapy  Higher dosages will 
certainly include a more psychedelic component than 
occurs in administration of the NIMH IV protocol. 
Not all ketamine experiences are positive and 
easy (see Kolp et al., this issue). Potential use by any route 
includes the possibility of having difficult experiences, 
best served by presence in a supportive, safe setting. 
With positive preparation and administration in a safe 
and comfortable environment, given the physiological 
safety of ketamine, subjects may well derive great benefits 
from dissociative, altered state experiences. This has been 
the case with the psilocybin work being done at Johns 
Hopkins by Griffiths, Richards, McCann, and Jesse 
(2006), and in the MDMA assisted psychotherapy work 
reported by Mithoefer, Wagner, Mithoefer, Jerome, and 
Doblin (2011) and the Multidisciplinary Association 
for Psychedelic Studies (MAPS). One can apply similar 
models for IM ketamine administration that would 
constitute a ketamine assisted psychotherapy protocol, 
without the encumbrances of IV administration and 
hospital settings.
The fact that there are disparities in reports 
about the efficacy of ketamine as an antidepressant at 
doses used in the NIMH protocol, and the possibility 
that higher doses may produce effects that are more 
robust and sustained than current formulations, calls 
for further explorations of ketamine’s effects—potential 
antidepressant, personality transformation, anti-
obsession, amongst others. Higher dosages will certainly 
include a more psychedelic component than occurs 
in administration of the NIMH IV protocol. With 
positive preparation and administration in a safe and 
comfortable environment, given the physiological safety 
of ketamine, subjects can generally be expected to be able 
to emotionally handle their experiences. This has been 
the case with the psilocybin work being done at Johns 
Hopkins by Griffiths, Richards, McCann, and Jesse 
(2006), and in the MDMA assisted psychotherapy work 
reported by Mithoefer, Wagner, Mithoefer, Jerome, and 
Doblin (2011) and the Multidisciplinary Association for 
Psychedelic Studies (MAPS). However, in rare instances 
profound nadir experiences may also occur (see Kolp et 
al., this issue). One can apply similar models for ketamine 
administration that would constitute a ketamine assisted 
psychotherapy protocol, without the encumbrances of IV 
administration and hospital settings.
Limitations and Delimitations
 The small sample size limits the validity of this 
study, and qualitative results are not widely generalizable. 
The fact that subjects were experienced ketamine users 
may have biased their attitudes toward or perceptions 
of the effects of the intervention. Participants were not 
significantly communicative during intervention, so 
qualitative reports were thin. Group discussion was not 
recorded and the presence of the researcher in the group 
discussion may have influenced the recommendations.
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